Drugs / Ravidasvir
Ravidasvir
also known as
PPI-668 · BI 238630 · BI 238630 CL2 · BL-238630 DIHYDROCHLORIDE · PPI-668 free base · Ravidasvir dihydrochloride · ravidasvir hydrochloride · RDV
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT04358523 | Mar → Dec 2020 | — | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03430830 | Jan → Apr 2018 | chronic hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03288636 | Aug → Sep 2017 | hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03020134 | Jul → Aug 2016 | — | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02258321 | Oct 2014 | — | Presidio Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01979484 | Oct → Nov 2013 | — | Presidio Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01786382 | Feb → Mar 2013 | — | Presidio Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01448200 | Oct 2011 → Nov 2012 | chronic hepatitis C virus infection | Presidio Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03020095 | Aug 2015 → Aug 2016 | chronic hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT04885855 | Mar 2021 → Dec 2023 | chronic hepatitis C virus infection | Muhammad Radzi Abu Hassan | Completed | No outcome recorded |
| Phase 2/3 | NCT03362814 | Jul 2017 → Dec 2018 | hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT02961426 | Sep 2016 → Aug 2021 | hepatitis C virus infection | Drugs for Neglected Diseases | Unknown | No outcome recorded |
| Phase 2/3 | NCT02371408 | Jan 2015 → Jan 2016 | chronic hepatitis C virus infection | Pharco Pharmaceuticals | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01859962 Comparator | May 2013 → May 2014 | chronic hepatitis C virus infection | Presidio Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ravidasvir | “ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg” NCT04358523 ↗ |
| Known as | BI 238630 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3121849 ↗ |
| Known as | BI 238630 CL2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3121849 ↗ |
| Known as | BL-238630 DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3121849 ↗ |
| Known as | PPI-668 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01859962 ↗ |
| Known as | PPI-668 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL3121849 ↗ |
| Known as | Ravidasvir dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL3121849 ↗ |
| Known as | ravidasvir hydrochloride | “The study will assess the efficacy of PPI-668 (USAN: ravidasvir hydrochloride) in combination with sofosbuvir, with or without ribavirin, in the following Egyptian HCV gt-4...” NCT02371408 ↗ |
| Known as | RDV | “Ravidasvir (RDV) is a novel oral hepatitis C virus NS5A inhibitor.” PMID 34252301 ↗ Jul 2021 |
| Action | Inhibit | “NS5A inhibitor” NCT01448200 ↗ |
| Modality | Small molecule | “Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor” NCT04885855 ↗ |
| Route | Oral | “new oral hepatitis C drug ravidasvir in combination with the approved oral drug sofosbuvir” PMID 28935432 ↗ Sep 2017 |